Monoclonal Antibody Use for Coronavirus Disease 2019 in Pediatric Patients: A Multicenter Retrospective Study. Issue 3 (17th March 2023)

• Record Type: Journal Article
• Authors: Sherman, Gilad; Lamb, Gabriella S; Sharma, Tanvi S; Lloyd, Elizabeth C; Nagel, Jerod; Dandam, Nada N; Oliveira, Carlos R; Sheikha, Hassan S; Anosike, Brenda I; Lee, Philip; Vora, Surabhi B; Patel, Karisma; Sue, Paul K; Rubbab, Beenish; Yarbrough, April M; Ganapathi, Lakshmi; Nakamura, Mari M
• Is Part Of: Journal of the Pediatric Infectious Diseases Society. Volume 12:Issue 3(2023)
• Page Start: 152
• Page End: 155
• Publication Date: 2023-03-17
• Subjects: bamlanivimab and etesevimab -- casirivimab and imdevimab -- COVID-19 -- monoclonal antibodies -- pediatric -- SARS-CoV-2; Communicable diseases in children -- Periodicals; Children -- Diseases -- Periodicals; 618.929
• DOI: 10.1093/jpids/piac124
• Languages: English
• ISSNs: 2048-7193

Abstract

Abstract: Monoclonal antibodies for COVID-19 are authorized in high-risk patients aged ≥12 years, but evidence in pediatric patients is limited. In our cohort of 142 patients treated at seven pediatric hospitals between 12/1/20 and 7/31/21, 9% developed adverse events, 6% were admitted for COVID-19 within 30 days, and none received ventilatory support or died.